Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 234392
                    [Title] => GSK, Boehringer Ingelheim co-sponsor landmark trial
                    [Summary] => GlaxoSmithKline (GSK) joins forces with Boehringer Ingelheim (BI) to co-sponsor the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Program, the world’s largest ever cardiovascular protection trial using an angiotensin receptor blocker (ARB).


The program, which will enroll over 29,000 patients, will examine the preventive effects of telmisartan, either alone or in combination with the ACE inhibitor ramipril, on stroke, heart attack, cardiovascular death and hospitalization due to congestive heart failure. 


                    [DatePublished] => 2004-01-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 231209
                    [Title] => Improving survival of high-risk heart patients
                    [Summary] => The greatest concern for high-risk heart patients is that their long-term survival may be significantly compromised. 


Two of the world’s highly respected research-based pharmaceutical and healthcare companies have pooled their resources to sponsor what is believed to be the largest landmark cardiovascular protection trial of this decade which is expected to answer some questions on how to optimize cardiac care for patients at high risk and improve their long-term survival.


                    [DatePublished] => 2003-12-11 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 224399
                    [Title] => Trial seeks optimum hypertension mg’t
                    [Summary] => The growth in the medical understanding of heart disease that has been achieved with well-designed researches and clinical trials is one of the greatest achievements in medical history. Medical researchers all over the world have slowly but continuously provided the answers to many questions on heart-related diseases. 


                    [DatePublished] => 2003-10-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 221974
                    [Title] => ONTARGET: Protecting high-risk patients
                    [Summary] => Medical scientists and researchers are continuously undertaking researches and clinical trials which are answering a lot of previously unanswered questions in modern medicine. 


Clinical trials have already convincingly shown that sustained management of hypertension significantly reduces the risk of cardiovascular events such as heart attack, heart failure, stroke and heart-related deaths. 


Among the most effective medicines available to physicians is telmisartan, a medicine belonging to the angiotensin II receptor blocker class of drugs. 


                    [DatePublished] => 2003-09-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

TELMISARTAN RANDOMIZED ASSESSMENT STUDY

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 234392
                    [Title] => GSK, Boehringer Ingelheim co-sponsor landmark trial
                    [Summary] => GlaxoSmithKline (GSK) joins forces with Boehringer Ingelheim (BI) to co-sponsor the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Program, the world’s largest ever cardiovascular protection trial using an angiotensin receptor blocker (ARB).


The program, which will enroll over 29,000 patients, will examine the preventive effects of telmisartan, either alone or in combination with the ACE inhibitor ramipril, on stroke, heart attack, cardiovascular death and hospitalization due to congestive heart failure. 


                    [DatePublished] => 2004-01-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 231209
                    [Title] => Improving survival of high-risk heart patients
                    [Summary] => The greatest concern for high-risk heart patients is that their long-term survival may be significantly compromised. 


Two of the world’s highly respected research-based pharmaceutical and healthcare companies have pooled their resources to sponsor what is believed to be the largest landmark cardiovascular protection trial of this decade which is expected to answer some questions on how to optimize cardiac care for patients at high risk and improve their long-term survival.


                    [DatePublished] => 2003-12-11 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 224399
                    [Title] => Trial seeks optimum hypertension mg’t
                    [Summary] => The growth in the medical understanding of heart disease that has been achieved with well-designed researches and clinical trials is one of the greatest achievements in medical history. Medical researchers all over the world have slowly but continuously provided the answers to many questions on heart-related diseases. 


                    [DatePublished] => 2003-10-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 221974
                    [Title] => ONTARGET: Protecting high-risk patients
                    [Summary] => Medical scientists and researchers are continuously undertaking researches and clinical trials which are answering a lot of previously unanswered questions in modern medicine. 


Clinical trials have already convincingly shown that sustained management of hypertension significantly reduces the risk of cardiovascular events such as heart attack, heart failure, stroke and heart-related deaths. 


Among the most effective medicines available to physicians is telmisartan, a medicine belonging to the angiotensin II receptor blocker class of drugs. 


                    [DatePublished] => 2003-09-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

GSK, Boehringer Ingelheim co-sponsor landmark trial

January 8, 2004 - 12:00am

GlaxoSmithKline (GSK) joins forces with Boehringer Ingelheim (BI) to co-sponsor the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Program, the world’s largest ever...

Science and Environment

Improving survival of high-risk heart patients

December 11, 2003 - 12:00am

The greatest concern for high-risk heart patients is that their long-term survival may be significantly compromised. Two of the world’s highly respected research-based pharmaceutical and healthcare companies...

Science and Environment

Trial seeks optimum hypertension mg’t

October 16, 2003 - 12:00am

The growth in the medical understanding of heart disease that has been achieved with well-designed researches and clinical trials is one of the greatest achievements in medical history. Medical researchers all over...

Science and Environment

ONTARGET: Protecting high-risk patients

September 25, 2003 - 12:00am

Medical scientists and researchers are continuously undertaking researches and clinical trials which are answering a lot of previously unanswered questions in modern medicine. Clinical trials have already convincingly...

Science and Environment